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Abstract
Glioblastoma multiforme is extraordinarily aggressive
due to the propensity of cells to migrate away from the
tumor core into the surrounding normal brain. In this
report, we investigated the role of proline-rich tyrosine
kinase 2 (Pyk2) and FAK with regard to influencing
glioma cell phenotypes. Expression of Pyk2 stimulated
glioma cell migration, whereas expression of FAK in-
hibited glioma cell migration and stimulated cell cycle
progression. Pyk2 autophosphorylation was neces-
sary, but not sufficient, to stimulate cellular migration.
The N-terminal domain of Pyk2 is required for stimu-
lation of migration as an N-terminally deleted variant
of Pyk2 failed to stimulate migration, whereas expres-
sion of an autonomous Pyk2 N-terminal domain
inhibited cell migration. Substitution of the C-terminal
domain of Pyk2 with the corresponding domain of FAK
stimulated cell migration as effectively as wild-type
Pyk2; however, substitution of the N-terminal domain
of Pyk2 with that of FAK inhibited cell migration, sub-
stantiating that the N-terminal domain of Pyk2 was
required to stimulate migration. Silencing of Pyk2 ex-
pression by RNA interference significantly inhibited
glioma migration. Cell migration was restored on re-
expression of Pyk2, but expression of FAK in Pyk2
knockdown cells failed to restore migration. We con-
clude that Pyk2 plays a central role in the migratory
behavior of glioblastomas.
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Introduction
Treatment of glioblastoma multiforme has been largely
unsuccessful due to the predisposition of individual tumor
cells to invade the surrounding normal brain. These invasive
cells substantially reduce the treatment efficacy of surgical
resection, radiation, and chemotherapy [1–5]. Although not
one of the more common tumors afflicting patients in the
United States (2% of all yearly deaths due to cancer, or
f13,000 deaths/year), glioblastomas are very aggressive
and are associated with amedian survival of less than 1 year
from initial diagnosis [6,7]. The molecular mechanisms
that regulate migration of gliomas from primary tumor sites
remain poorly understood. Invasion is a complex process in-
volving both receptor-mediated adhesion to components of
the extracellular matrix (ECM) and proteolytic modification
of the ECM. Integrin-mediated adhesive interactions play a
critical mechanical role in cellular migration by linking the ECM
to the intracellular cytoskeleton. Moreover, integrin ligation and
receptor clustering lead to assembly of the focal adhesion
complex, a complex protein scaffold enriched in signaling mole-
cules, leading to activation of intracellular signaling pathways
crucial to cell proliferation and survival [8–10]. Therefore,
integrin-mediated adhesion and signaling are uniquely situ-
ated to play a central role in the behavior of invasive glio-
mas. Indeed, the importance of integrin interactions with ECM
proteins on glioma adhesion and migration has been demon-
strated in previous reports [11–14].
The related nonreceptor tyrosine kinases, FAK and proline-
rich tyrosine kinase 2 (Pyk2), are important signaling effec-
tors linking integrin and growth factor receptor signaling to
cell proliferation, migration, survival, and apoptosis in many
cell types. FAK is the prototypical signaling effector coupling
integrin–matrix interactions to intracellular signaling events.
FAK is activated rapidly following integrin engagement and
exerts downstream effects by serving both as an effector ki-
nase as well as a scaffold protein for various molecules includ-
ing Src, paxillin, talin, p130cas, Grb2, Grb7, Graf, and PI3-K [15].
Considerable evidence supports the role of FAK in cell migra-
tion both in vitro and in vivo [16–18]. Furthermore, increased
FAKactivity has been correlatedwith increased cell proliferation
and cell cycle progression, which play integral roles in tumor
progression [19–21]. Indeed, overexpression of FAK promoted
malignant astrocytoma cell proliferation in vivo [22]. In contrast,
it has been reported that although FAK was localized to the
membrane of nonmigratory astrocytoma cells, it was largely
absent in migrating cells [23]. High levels of endogenous FAK
also have been correlated with reduced migratory rates of
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cultured glioma cells in vitro [24]. Furthermore, dephosphory-
lation and downregulation of FAK activity correlated posi-
tively with EGF-induced tumor cell invasion [25].
The related focal adhesion kinase Pyk2 has a conserved
domain structure and significant sequence identity to FAK
[26,27]. Although Pyk2 can interact with many of the same
proteins as FAK, it has a different primarymeans of activation
and a more limited tissue distribution. Notably, Pyk2 is highly
expressed in the central nervous system [28]. In contrast to
the more rigorously studied FAK, the cellular functions of
Pyk2 continue to be defined. Although FAK activity has been
readily linked to cell motility, a role for Pyk2 in cell migration
has only recently begun to be appreciated. In cell types that
naturally express Pyk2 but little or no FAK, such as NK cells,
monocytes, or osteoclasts, a critical role for Pyk2 in the
regulation of cytoskeletal organization and cell motility has
been established [29–32]. Therefore, in cells such as glio-
mas that express both kinases, the temporal balance be-
tween Pyk2 and FAK activity may ultimately regulate cell
growth and cell migration. The recent demonstration [33] of a
clear correlation between expression of FAK and Pyk2 and
increasingmalignancy suggests that the differential activity of
these two kinases may be particularly relevant to the regula-
tion of the proliferative or migratory behavior of these cells.
The current study investigated the functional contribu-
tions of FAK and Pyk2 in determining in vitro glioma cell
migration and proliferation. Expression of Pyk2 stimulated
glioma cell migration in a dose-dependent manner. Auto-
phosphorylation of Pyk2 Y402 was necessary but insufficient
for this phenotypic effect. The N-terminal FERM domain of
Pyk2 was required to stimulate migration and was capable of
inhibiting migration when expressed as an autonomous
fragment. In contrast, expression of FAK inhibited glioma
cell migration and stimulated cell cycle progression in a
dose-dependent manner. Knockdown of Pyk2 expression
by RNAi inhibited glioma cell migration in vitro and in organo-
typic brain slices. Reconstitution of Pyk2 expression in these
cells, but not FAK expression, restored glioma cell migra-
tion. These data further indicate that Pyk2 and FAK function
in the temporal development of the proliferative or migratory
behavior of glioma cells and may be useful therapeutic tar-
gets in malignant glioblastoma.
Materials and Methods
Antibodies
Affinity-purified polyclonal antibodies to the C-terminal por-
tion of FAK were obtained from Upstate Biotechnology (Lake
Placid, NY). Monoclonal antibody to the C-terminal portion of
Pyk2 was obtained from Transduction Laboratories (Lexing-
ton, KY). Anti-FLAG M2 monoclonal antibody was obtained
from Sigma (St. Louis, MO). Affinity-purified antibody to the
HA epitope tag was obtained from Upstate Biotechnology.
Adenoviral Expression Constructs
Recombinant adenoviruses encoding HA epitope-tagged
wild-type FAK was previously described [24]. To generate
FLAG epitope-tagged wild-type Pyk2, the coding sequence
or Pyk2 was cloned in-frame downstream of a 3 FLAG
epitope in pcDNA3. The Pyk2 phosphorylation-deficient
mutant Y402F was generated using the Quickchange site
directed mutagenesis system (Stratagene, La Jolla, CA). To
generate the Pyk2 N-terminal deletion mutant Pyk2D376, a
fragment encoding Pyk2 residue S376-E1009 was amplified
by polymerase chain reaction (PCR) and cloned in-frame
downstream of the 3 FLAG epitope in pcDNA3. The FLAG
epitope-tagged chimeric proteins designated Pyk/FAK and
FAK/Pyk were generated by splice overlap extension PCR
[34]. Pyk/FAK contains Pyk2 N-terminal residue M1-D665
fused to FAK residue P663-H1052. FAK/Pyk contains FAK
N-terminal residue M1-D662 fused to Pyk2 residue P666-
E1009. The Pyk2 FERM domain, encoding Pyk2 residue
R39-A367, was amplified by PCR and cloned in-frame
downstream of a 3 HA epitope in pcDNA3. A fragment
encoding Pyk2 residues 1 to 367 was amplified by PCR and
cloned downstream of a 3 HA epitope to generate a
construct designated Pyk NT. All sequences were verified
by DNA sequencing. Recombinant E1-deleted adenovirus
for each construct was prepared using the Ad-Easy system
as described [35].
Retroviral Constructs
The retroviral transfer vector pQGFP is a derivative of
the pQCXIX self-inactivating retroviral vector (Clontech,
Palo Alto, CA). The coding sequence for humanized Renilla
green fluorescent protein (GFP) was excised from plasmid
phrGFP-1 (Stratagene) and cloned into the Not–EcoRV
sites of pQCXIX to produce pQGFP. A transcriptional cas-
sette containing an oligonucleotide duplex encoding the
human Pyk2 small interfering RNA (siRNA) or FAK siRNA
was cloned downstream of the human U6 promoter or
cloned into the unique SalI site in the 3V LTR of pQGFP to
produce pGFP.U6Pyki or pGFP.U6FAKi, respectively. The
correct sequence and orientation of the U6-siRNA or U6-
siFAKi cassette were verified by direct DNA sequencing.
Viral stocks were prepared by cotransfecting the GP2-293
packaging cell line (Clontech) with pGFP.U6Pyki or
pGFP.U6FAKi and pVSV-G (Clontech). Forty-eight hours
after transfection, the supernatant was removed, filtered
through a 0.45-mm filter, and spun at 50,000g for 1.5 hours.
The pelleted virus was resuspended in 400 ml of Dulbecco’s
modified Eagle’s medium (DMEM) and added to target
cells with 5 mg/ml polybrene. Forty-eight hours after infec-
tion, cells were harvested and GFP-positive cells were
collected by mass sorting on a FACS Vantage flow cytome-
ter (BD Biosciences, San Jose, CA). The coding sequence
of Discosoma red fluorescent protein (RFP) from pCMV-
DsRed-Express (Clontech) was ligated into pQCXIX to
produce the retroviral transfer vector, pQDsRed. SF767
cells stably transduced with RFP were produced as de-
scribed above.
Cell Culture
Established human malignant glioblastoma cell lines
SF767 and G112 were routinely passaged in DMEM
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containing 10% fetal bovine serum, 1% nonessential amino
acids, 2 mM glutamine, 100 U/ml penicillin, and 10 mg/ml
streptomycin. For adenoviral infections, 2.5  105 cells were
added to each well of a six-well plate and cultured for
24 hours before infection.
Immunoblotting
Cells were washed in cold phosphate-buffered saline
(PBS) and lysed by addition of 1 ml of ice-cold RIPA buffer:
150 mM NaCl, 10 mM Tris, pH 7.2, 1 mM EGTA, 1 mM
orthovanadate, 1% Triton X-100, 1% Na deoxycholate,
1% SDS, 100 mM leupeptin, 5 IU/ml aprotinin, 10 mg/ml
soybean trypsin inhibitor, 10 mM benzamidine, and 1 mM
phenylmethylsulfonyl fluoride, and incubated on ice for
30 minutes. Lysates were clarified by centrifugation at
16,000g for 10 minutes at 4jC. The protein content of the
lysate was determined using the BCA assay (Pierce, Rock-
ford, IL). For immunoblotting, equal amounts of protein
(10–20 mg) were electrophoresed on 8% to 16% gradient
SDS-PAGE gels (Novex, Carlsbad, CA) and transferred to
nitrocellulose. Immunoblotting of transferred proteins was
performed with the appropriate antibodies at the indicated
concentrations for 1 hour at room temperature and was
visualized by enhanced chemiluminescence (Perkin Elmer
Life Sciences, Boston, MA). Signals were quantified by
densitometry utilizing Kodak 1D Image Analysis Software.
Efficiency of transfer was routinely monitored by immuno-
blotting for actin. No significant differences in the amount of
actin in the transfers were observed.
Radial Migration Assay
A monolayer radial migration assay was used as previ-
ously described [36]. Briefly, slides containing 10 individual
7-mm circular seeding areas surrounded by a hydrophobic
template mask (Creative Scientific Methods, Inc., Phoenix,
AZ) were coated with laminin at either 1 or 10 mg/ml. A
coating concentration of 1 mg/ml was used to minimize the
intrinsic migratory rate, thus increasing the positive effect
size relative to control. Assays assessing FAK dose re-
sponse utilized a higher laminin coating concentration
(10 mg/ml) to maximize the intrinsic migratory rate and to
accentuate the evaluation of the inhibitory effect. Cells
were routinely infected with 2, 5, 10, 20, and 40 multiplici-
ties of infection (MOI) of recombinant adenoviruses and
cultured for 16 hours before harvest. Infected cells were
resuspended in DMEM containing 10% serum and seeded
at a density of 2500 cells/well (internal diameter of 1 mm)
of a Cell Sedimentation Manifold (Creative Scientific Meth-
ods, Inc.). After overnight incubation (16 hours), the mani-
fold was removed and an initial measurement (t0) of the
diameter of the cell colony was made using an inverted
microscope (Axiovert; Carl Zeiss, Thornwood, NY) and
image analysis equipment (Scion Image, Frederick, MD).
The change in the diameter of the cell population over time
was determined at 24 hours following the initial measure-
ment. Slopes of the lines derived from the measurements
(radius versus time) were used to calculate the migration
rate of the cells. Linear migration from the initial seeded
area at t0 was determined for at least 10 replicate
samples for each infected construct. Specific migration
rates were calculated by normalizing the measurements
to nonspecific migration on BSA. The absolute migration
and migratory rates were calculated and group means
were determined.
Organotypic Brain Slice Invasion Assay
Slice cultures of whole brains were produced from adult
rats essentially as described [37]. Four- to 6-week–old male
Wistar rats were sacrificed by isofluorane inhalation, then rat
brains were removed from the skull and immediately placed
into sterile ice-cold PBS. The cold brains were coronally
sectioned with a vibratome (OTS-4000; Electron Microscopy
Sciences, Hatfield, PA) into 400 mm slices at +1.75 to +1.0
bregma and the slices placed aseptically onto transwell
(8 mm pore size) membranes in six-well dishes. Culture
media (DMEM, 10% FCS, 6.5 mg/ml glucose, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 2.5 mg/ml amphoter-
icin B) were added into each well to a point just below that
which would cover the brain slice. Wild-type SF767 cells
(stably expressing RFP) or SFPyk2i cells (expressing GFP)
were grown to subconfluency and 1  105 cells (in 0.5 ml)
were deposited onto each caudoputamen of the brain slice.
Cells are allowed to attach to the brain surface (f1 hour)
before the media were added to just the surface of the slice.
The slices were incubated at 37jC for 5 days, rinsed with
PBS, and fixed in 4% paraformaldehyde. The extent of
glioma cell invasion into the brain slice was quantitated by
optical sectioning with a LSM 510 confocal microscope (Carl
Zeiss, Thornwood, NY).
Cell Cycle Progression Assay
SF767 cells and G112 cells were seeded into six-well
plates and infected with virus after 24 hours. Twenty-four
hours postinfection, cells were washed once with PBS,
removed from the plate with trypsin, and washed in complete
media. The cells were again washed in PBS, centrifuged,
and resuspended in 1 ml of PBS. Cells were then fixed by
adding cold ethanol dropwise while vortexing, followed by
incubation on ice for 1 hour. Cells were washed in PBS and
resuspended in 100 ml of RNase A (100 mg/ml) for 5 minutes
at room temperature. The cells were then stained in 400 ml of
propidium iodide (50 mg/ml) and detected on a Becton Dick-
inson FACScan (BD Biosciences) flow cytometer using a
488-nm laser. The percentage of cells in S-phase was
calculated using the Modfit program (Verity Software House,
Inc., Topsham, ME).
Statistics
Migration and proliferation data were imported to SAS
(Cary, NC), checked, and cleaned. Preliminarily, distributional
assumptions were tested using the Kolmogorov-Smirnov
test. No data set, within cell line or adhesion kinase, deviated
significantly from normality. Therefore, means and standard
deviations were chosen for statistical tests. Independent-
sample t tests were used for analyses involving two samples,
and ANOVA, with post-hoc Scheffe tests, for tests involving
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more than two samples. All tests are two-tailed (criterion level,
P < .05).
Results
Glioma Cell Migration Is Stimulated by Pyk2 Expression
and Inhibited by FAK Expression
The effect of expression of Pyk2 or FAK on glioma cell
migration was assessed in the SF767 and G112 glioma cell
lines. These two cell lines were chosen as they exhibit high
and low intrinsic migration rates, respectively, that correlate
with opposite expression/activity patterns with regard to
Pyk2 and FAK [24]. Thus, SF767 cells express significantly
higher levels of Pyk2 relative to FAK and a high intrinsic
migration rate. Conversely, G112 cells express higher levels
of FAK relative to Pyk2 and exhibit a lower intrinsic migra-
tion rate. To further investigate the role of Pyk2 and FAK in
glioma cell migration, dose response experiments were
performed in which glioma cells were infected with increas-
ing MOI of recombinant adenoviruses encoding Pyk2 or
FAK. The effects of increasing Pyk2 or FAK expression were
examined with a monolayer migration assay.
To investigate the effect of Pyk2 on cell migration, infected
cells were plated on a low laminin coating concentration
(1 mg/ml) to allow better discrimination of gain of function.
Increasing expression of wild-type Pyk2 resulted in a sig-
nificant dose-dependent increase in migration rate (Figure 1,
A and B). This effect was observed in both the highly mi-
gratory SF767 and the slower migrating G112 cell lines.
SF767 and G112 cells infected with 20 MOI of the control
adenovirus encoding b-galactosidase migrated at a rate of
66 ± 11 mm/day (mean ± SD) and 42 ± 7 mm/day, respec-
tively. In contrast, the migration rate of SF767 cells and G112
cells infected with 20 MOI of adenovirus encoding Pyk2 in-
creased to 113.6 ± 14.1 and 88.8 ± 7.7 mm/day, respectively.
To investigate the role of FAK in glioma cell migration,
SF767 and G112 cells were infected with wild-type FAK at
varying MOI and plated on a high laminin substrate con-
centration (10 mg/ml) to better observe any loss of migratory
function. Expression of FAK significantly inhibited the
migration of both cell lines (Figure 1, C and D). SF767 cells
expressing b-galactosidase (20MOI) migrated at 98 ± 12 mm/
Figure 1. Glioma cell migration is stimulated by Pyk2 expression and inhibited by FAK expression. SF767 (A and C) or G112 (B and D) glioma cell lines were
infected with recombinant adenoviruses encoding Pyk2 or FAK at the indicated MOI and migration rate on laminin measured with a monolayer migration assay.
Migration rates of infected cells were derived from slopes of lines from measurements of radii of cell population versus time. Cells were plated on 1 lg/ml laminin
(A and B) or on 10 lg/ml laminin (C and D). Values represent mean ± SD of 10 replicate samples. Expression of Pyk2 or FAK was detected by immunoblotting of
cell lysates with anti-FLAG or anti-HA antibodies, respectively. *P < .05.
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day, whereas expression of FAK (20 MOI) substantially
reduced the migration rate to 2.5 ± 10.2 mm/day. At the
highest level of FAK expression (40 MOI), a negative mi-
gration rate was derived as the cells were observed to round
up and detach from the edges of the assay accounting for
these observations. Similar results were observed in the
G112 cells. G112 cells expressing 20MOI of b-galactosidase
migrated at 55.9+8.3 mm/day, whereas those cells infected
with 20 MOI FAK migrated at 11.6 ± 3.9 mm/day.
FAK Expression Induces Glioma Cell Proliferation
Overexpression of FAK in glioma cells resulted in statis-
tically higher expression of the nuclear proliferation marker
Ki67 [38] in both the core and rim populations in the radial
migration assay format, whereas Pyk2 expression reduced
Ki67 expression in these cell populations [24]. To substan-
tiate these immunohistochemical data, we examined the
effect of FAK or Pyk2 expression on glioma cell cycle prog-
ression. Subconfluent cultures of SF767 or G112 cells were
infected with varying MOI of the control b-galactosidase
virus, epitope-tagged wild-type Pyk2, or FAK, and the per-
centage of cells in S-phase was determined by flow cyto-
metry (Figure 2). TheG112 cell line was observed in all cases
to proliferate to a greater degree than the SF767 cells.
Increasing b-galactosidase MOI in G112 did not significantly
affect the percentage of cells in S-phase (range 36.8–34.2,
P = NS). However, increasing FAK expression increased
the percentage of G112 cells in S-phase (range 40.1 ± 1.7%
to 61.1 ± 2.3%) (Figure 2A). Infection of SF767 cells with
b-galactosidase at increasing MOI also did not result in a
significant change in the percentage of cells in S-phase
(range 28.57–29.61; P = NS). Similar to the results obtained
with G112 cells, expression of FAK in SF767 cells increased
the percentage of cells in S-phase in a dose-dependent
manner (range 32.5 ± 2.4% to 39.9 ± 3.1%) (Figure 2B).
Because WT FAK was observed to exert a positive effect
on cell cycle progression, we investigated the effect of in-
creasing expression of WT Pyk2 on the percentage of SF767
and G112 cells in S-phase. Increasing expression of Pyk2
in SF767 cells did not change the percentage of cells in
S-phase relative to cells infected with a matching MOI of the
control b-galactosidase virus. In contrast, expression of Pyk2
decreased the percentage of G112 cells in S-phase relative
to control b-galactosidase–infected cells. Together, these
results are consistent with the differential effects of FAK
and Pyk2 on cell cycle progression [20,21,39].
Stimulation of Glioma Cell Migration by Pyk2 Requires
the N-terminal Domain
To identify the required structural or functional domains
of Pyk2 required for its stimulatory effect on glioma cell mi-
gration, we generated several variant forms of Pyk2. These
Pyk2 variants were expressed in SF767 cells (MOI = 20)
and their effects on migration were analyzed with the radial
migration assay (Figure 3). Pyk2 stimulation of cell migration
required kinase activity because the expression of the cata-
lytically defective mutant Pyk2 K457A inhibited SF767 cell
migration. Similarly, the autophosphorylation site of Pyk2,
Y402, was required for Pyk2 to stimulate migration because
expression of the Pyk2 Y402F mutant inhibited cell migra-
tion relative to control SF767 cells infected with a matching
MOI of b-galactosidase (43.0 ± 5.9 vs 78.8 ± 10.4 mm/
day, respectively).
To further investigate the importance of the autophos-
phorylation site, we examined the effect of expressing a
Pyk2 variant that is constitutively phosphorylated. Similar
to the results observed following truncation of the N-
terminal portion of FAK [40], deletion of the N-terminal
376 amino acids of Pyk2 results in a variant Pyk2
(Pyk2D376) that maintains a high level of constitutive
phosphorylation at Y402 (data not shown). Interestingly,
expression of Pyk2D376 did not stimulate migration relative
Figure 2. FAK expression stimulates glioma cell proliferation. Subconfluent
cultures of G112 or SF767 cells were infected with varying MOI of the control
-galactosidase, wild-type FAK, or wild-type Pyk2. The percentage of cells in
S-phase was determined by flow cytometry 24 hours after infection. (A)
Expression of FAK significantly increased the percentage of G112 cells in S-
phase in a dose-dependent manner (*P V .01). In contrast, expression of
Pyk2 decreased the percentage of cells in S-phase relative to control infected
cells (*P < .05). (B) Expression of FAK increased the percentage of
SF767 cells in S-phase in a dose-dependent manner (*P < .001). Pyk2 did
not alter the percentage of SF767 cell in S-phase compared to the control
-galactosidase– infected cells.
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to control cells (Figure 3). SF767 cells expressing Pyk2D376
migrated at 69.1 ± 10.2 mm/day compared to control
b-galactosidase–expressing cells that migrated at 78.8 ±
10.4 mm/day (P = NS). Together, these results indicate that
phosphorylation of Y402 was necessary but not sufficient
to stimulate glioma cell migration. Moreover, these results
suggested that the N-terminal domain of Pyk2 was required
for the stimulation of glioma cell migration. To further
investigate the requirement of the Pyk2 N-terminal domain,
we examined the effect of expressing autonomous Pyk2
N-terminal domain fragments. SF767 cells were infected
(MOI = 20) with a construct that encodes Pyk2 residues 1 to
367 (Pyk NT), or with a construct encoding Pyk2 residues
39 to 367 corresponding to the divergent FERM domain [41].
Expression of either the Pyk NT domain (47.9 ± 7.7 mm/day)
or the Pyk2 FERM domain (21.0 ± 8.2 mm/day) significantly
inhibited cell migration relative to cells expressing the control
b-galactosidase protein (78.8 ± 10.4 mm/day) (Figure 3).
Inhibition of cell migration by expression of the Pyk2 FERM
domain was not due to a decrease in expression of en-
dogenous Pyk2 (data not shown).
The requirement of the Pyk2 N-terminal domain for
the stimulation of glioma cell migration was substantiated
through the use of chimeric proteins. The chimera desig-
nated Pyk/FAK contains the N-terminal and kinase domains
of Pyk2 fused to the C-terminal domain of FAK. The
reciprocal chimera FAK/Pyk contains the N-terminal and
kinase domains of FAK fused to the C-terminal domain of
Pyk2. Expression of the Pyk/FAK chimera stimulated
SF767 migration (Figure 3) to the same degree as wild-type
Pyk2 (124.2 ± 10.5 mm/day for Pyk/FAK vs 132.1 ± 16.7
mm/day for WT Pyk2; P = NS). Conversely, expression of the
FAK/Pyk construct significantly inhibited migration (40.5 ±
9.4 mm/day) compared to SF767 cells infected with an equiv-
alent MOI of b-galactosidase (78 ± 10.4 mm/day) (Figure 3).
These data indicate that the N-terminal domain of Pyk2
was required for stimulating cell migration, that the highly
similar FAK N-terminal domain could not substitute for Pyk2,
and that the C-terminal domain of Pyk2 was not required
for stimulation of cell migration.
Effect of Silencing Pyk2 or FAK Expression on Glioma
Cell Migration
The expression of both FAK and Pyk2 in the established
glioma cell lines adds a level of complexity to the interpre-
tation of experimental results. To overcome this limitation,
we have utilized siRNA to knock down the expression of
Pyk2 or FAK in SF767 cells. To generate glioma cell lines
with a stable knockdown of Pyk2 or FAK expression, SF767
cells were transduced with a retrovirus expressing both a
fluorescent tag and an siRNA targeting human Pyk2 or
FAK. The fluorescent tag, humanized Renilla GFP, is ex-
pressed by the CMV immediate early promoter, whereas
expression of the siRNA targeting Pyk2 is driven by the
human U6 promoter. SF767 cells were infected with the
retrovirus and GFP-positive knockdown cells (designated
SFPyk2i or SFFAKi) were collected by mass sorting on a
flow cytometer. Mass sorting of cells obviates concerns
over results obtained with individual clones. Immunoblot-
ting of SF767 or SFPyk2i cell lysates demonstrated that
the Pyk2 siRNA effectively knocked down the expression
of Pyk2 greater than 95% relative to parental SF767
cells (Figure 4A). The knockdown was specific for Pyk2
as immunoblots confirmed that the expression of FAK
was equivalent in SF767 and SFPyk2i cells. Similarly,
immunoblotting of SF767 and SFFAKi cell lysates demon-
strated that the FAK siRNA effectively knocked down the
expression of FAK, whereas expression of Pyk2 was un-
changed between the SF767 and SFFAKi cell lines
(Figure 4B).
The effect of silencing expression of Pyk2 or FAK ex-
pression on SF767 migration was investigated with the in
vitro migration assay (Figure 5). Knockdown of Pyk2 expres-
sion significantly reduced the migration rate of SFPyk2i cells
compared to the wild-type SF767 cells in the radial migra-
tion assay. The wild-type SF767 cells migrated at 101.4 ±
6.6 mm/day compared to the SFPyk2i cell line, which migrated
at 44.4 ± 7.1 mm/day. In contrast, knockdown of FAK ex-
pression only slightly reduced the migration rate of SFFAKi
cells compared to the wild-type SF767 cells (86.5 ± 8.2 vs
101.4 ± 6.6 mm/day).
Figure 3. Stimulation of glioma cell migration by Pyk2 requires the N-terminal
domain. (A) SF767 cells were infected with adenoviruses encoding -
galactosidase, wild-type Pyk2, or the indicated Pyk2 variants (MOI = 20).
Sixteen hours after infection, cells were seeded onto laminin (1 lg/ml) and
migration rate was determined 24 hours postseeding. Values are mean ± SD
of 10 replicate samples (*P < .01). (B) Expression of each of the epitope-
tagged constructs was detected by blotting cell lysates with anti-Flag or anti-
HA antibodies as indicated.
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Knockdown of Pyk2 expression in SF767 cells signifi-
cantly inhibited cell migration despite the fact that endog-
enous FAK levels did not differ between the control SF767
cells and the SFPyk2i cells. This suggests the possibility
that the residual migration observed in the SFPyk2i cells
was due to the endogenous FAK. To further investigate
the function of FAK and Pyk2 in glioma cell migration, we
examined the effect of overexpression of FAK and re-
expression of Pyk2 in theSFPyk2i cells. As shown in Figure 5,
expression of wild-type FAK in SFPyk2i cells did not res-
cue their migration deficit relative to SFPyk2i cells (30 ± 4.6
vs 44.4 ± 7.1 mm/day). To reconstitute Pyk2 expression,
SFPyk2i cells were infected with an epitope-tagged rat
Pyk2 construct that differs from the corresponding hu-
man sequence by 1 bp over the targeted sequence. Immu-
noblotting of SKPyk2i cells infected with adenoviruses
expressing rat Pyk2 demonstrated significant expression
of Pyk2. In contrast to the effect of expression of FAK,
reconstitution of Pyk2 expression restored migration to
SFPyk2i cells. SFPyk2i cells re-expressing Pyk2 migrated
at 129.5 ± 8.2 vs 44.4 ± 7.1 mm/day for the SFPyk2i cells
and 50.9 ± 5.5 mm/day for SFPyk2i cells infected with a
matching MOI of adenovirus expressing the control protein,
b-galactosidase. Similarly, Pyk2 expression in SFFAKi cells
resulted in a significant increase in the migration rate of
the SFFAKi cells compared to control b-galactosidase–
expressing cells (134.2 ± 8.2 vs 86.2 ± 8.0 mm/day). To
reconstitute FAK expression in the SFFAKi cells, SFFAKi
cells were infected with an epitope-tagged murine FAK con-
struct that differs from the corresponding human sequence
by 1 bp over the targeted sequence. FAK reconstitution
in the SFFAKi cells did not significantly alter the migra-
tion rate of SFFAKi cells compared to b-galactosidase–
expressing cells (77.8 ± 4.5 vs 86.2 ± 8.0 mm/day). This
effect is different from that observed following expression
of FAK in the SFPyk2i cells, which retain the expression of
endogenous FAK. Expression of FAK in the SFPyk2i cells
augments the endogenous FAK already present and further
decreases the migration rate of SFPyk2i cells. In contrast,
expression of FAK at 20 MOI in the SFFAKi cells brings
the level of FAK in these cells to a level that is slightly
greater than the amount of endogenous FAK in the paren-
tal SF767 cells. This is consistent with the observation that
SFFAKi cells infected with 20 MOI of FAK migrate slower
than wild-type SF767 cells (compare the first and last lanes
of Figure 5). Together, these results confirm a central role
for Pyk2 in glioma cell migration and suggest that the
ultimate ratio between Pyk2 and FAK expression likely lies
at the heart of the different functional responses.
The effect of knockdown of Pyk2 expression on cell inva-
sion was also examined in a more authentic brain matrix
utilizing an ex vivo organotypic rat brain slice assay [37].
Wild-type SF767 cells stably transduced with a retrovirus
expressing RFP or SFPyk2i cells (GFP) were seeded onto
the hemicaudoputamen, a rat brain slice, and allowed to in-
vade into the matrix for 5 days. Greater numbers of the
SFPyk2i were present at the site of implantation on the
surface of the slice after 5 days (Figure 6, top panel )
compared to the wild-type SF767 cells, suggesting impaired
invasion into the matrix. To investigate invasion into the
slice, optical sectioning by confocal microscopy was per-
formed. Greater numbers of SFPyk2i cells were also present
Figure 4. Silencing of Pyk2 and FAK expression in SF767 glioma cells.
SF767 glioma cells were infected with a retrovirus expressing both a GFP tag
and an siRNA targeting human Pyk2 or an siRNA targeting FAK. Forty-eight
hours after infection, GFP-positive cells were collected by mass sorting on a
FACS Vantage flow cytometer. (A) Top panel: Lysates of wild-type SF767
cells or SFPyk2i cells were immunoblotted with antibodies specific for Pyk2 or
FAK. Bottom panel: FACS histogram of GFP expression in the mass-sorted
cell population. (B) Top panel: Lysates of wild-type SF767 cells or SFFAKi
cells were immunoblotted with antibodies specific for Pyk2 or FAK. Bottom
panel: FACS histogram of GFP expression in the mass-sorted cell population.
Figure 5. Reconstitution of Pyk2 expression but not FAK restores glioma cell
migration. Wild-type SF767, SFPyk2i, or SFFAKi cells were infected (MOI =
20) with recombinant adenoviruses expressing -galactosidase, FLAG-
tagged Pyk2, or HA-tagged FAK, plated on laminin (1 lg/ml), and migration
rates were determined with the radial migration assay. Values represent
mean ± SD of 10 replicate samples. Matching aliquots of cells were lysed and
lysates were immunoblotted with the indicated antibodies (*P < .01).
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50 mm below the surface compared to the wild-type SF767
cells (Figure 6, bottom panel ). Wild-type SF767 cells in-
vaded to a depth of 128 mm compared to a depth of 82 mm
for the SFPyk2i cells (Figure 6, middle panel ). These data
corroborate the in vitro migration assay results and further
support a role for Pyk2 in migration and invasion both in vitro
and in vivo.
Discussion
The oncology of invasive gliomas is firmly rooted in the
inverse relationship between migration and proliferation.
Decreased proliferative activity and increased resistance to
therapeutic cytotoxic agents accompany the increased com-
mitment to invasion. The intracellular signaling networks and
the critical signaling effectors that regulate temporal changes
in glioblastoma proliferation and migration remain poorly
defined. The current studies further define the functional role
of Pyk2 and FAK in glioma cell migration and proliferation.
The major findings of this report are: 1) expression of Pyk2
stimulated glioma cell migration in a dose-dependent man-
ner; 2) expression of FAK inhibited glioma cell migration and
stimulated cell cycle progression in a dose-dependent man-
ner; 3) autophosphorylation of Pyk2 was required but not
sufficient to stimulate cell migration; 4) the N-terminal do-
main of Pyk2 is required for stimulation of migration as an
N-terminally deleted variant of Pyk2 failed to stimulate the
migration and expression of an autonomous Pyk2 N-terminal
fragment and inhibited cell migration; 5) silencing of Pyk2
expression by RNAi significantly inhibited cell migration
in vitro and invasion in an authentic brain matrix; and
6) migration could be restored by reconstitution of Pyk2
expression but not by expression of FAK. These data confirm
that the related focal adhesion kinases, Pyk2 and FAK, are
important effectors in the temporal development of glioblas-
toma phenotype.
Results in the current report support our previous data
[24] indicating that glioma cell migration correlates positively
with Pyk2 activity. Expression of Pyk2 stimulated the migra-
tion of two different glioma cell lines in a dose-dependent
manner, whereas inactive forms of Pyk2 inhibited cell mi-
gration. Silencing of Pyk2 expression by RNAi significantly
inhibited, but did not completely abolish, migration. This
effect in glioma cells is different from that commonly ob-
served in a number of different cell types where FAK activity
has been commonly linked to cell motility. This is particularly
true for fibroblasts that notably do not express Pyk2. Inter-
estingly, FAK-null fibroblasts express a significant amount of
Pyk2, but its expression is not capable of compensating for
their migration deficiency [42,43]. Because Pyk2 is not
normally expressed in fibroblasts, the failure of Pyk2 to
compensate for FAK in promoting the migration of these
cells may potentially be due to the absence of cell type–
specific elements required to interact with Pyk2 in order for it
to mediate a promigratory effect. This might also be related
to cellular localization as targeting Pyk2 to focal contacts
rescued fibronectin-stimulated signaling and motility in
FAK-null cells [44]. A role for Pyk2 in cell migration and cyto-
skeletal organization has been established in cells such as
NK cells, monocytes, and osteoclasts that express Pyk2 but
little or no FAK [29–32]. Definitive evidence for the Pyk2
function in migration of specific cell types has been demon-
strated by studies performed with Pyk2-deficient mice.
Although Pyk2-deficient mice are viable and fertile, macro-
phages from these mice fail to become polarized, to undergo
membrane ruffling, or to migrate despite the normal expres-
sion of FAK in these cells [45]. Notably, integrin adhesion–
mediated activation of Rho and PI-3 kinase was significantly
compromised in Pyk2-null cells. Similarly, the migration of
B-lymphocytes in the absence or presence of chemokines
was impaired in Pyk2-null mice. Analogous to the results
reported in this study, in studies with brain microvascular
endothelial cells that, like glioma cells, express both Pyk2
and FAK, expression of Pyk2 stimulated migration whereas
expression of an inactive Pyk2 variant substantially inhibited
cell spreading and migration [46]. Pyk2 has also been
reported to be a point of convergence between G protein–
coupled receptors and receptor tyrosine kinases such as
EGFR and FGFR [47–49], which play central roles in the
activation of signaling networks critical to cell motility and
proliferation. Furthermore, Pyk2 has also recently been
identified as a comediator in triggering STAT3 activation
[50] and has been implicated in promoting breast carcinoma
invasion induced by heregulin stimulation [51]. Thus, the
observed role of Pyk2 in the stimulation of glioma cell
Figure 6. Silencing Pyk2 expression inhibits cell invasion in organotypic brain
slice. SF767 cells stably transduced with RFP (left panels) or SFPyk2i cells
expressing GFP (right panels) were seeded onto bilateral putamen of
organotypic rat brain slice and cultured for 5 days. The extent of cell invasion
was measured by optical sectioning by confocal microscopy. Images are at
the surface of the slice (top), or at the indicated depths and magnification.
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migration is consistent with a widening role for Pyk2 in cell
type–specific migration.
Proliferation and invasion are integral to the malignant
behavior of glioblastoma and its poor clinical prognosis.
The ‘‘go or grow’’ hypothesis proposes that cell division
and cell migration are temporally exclusive events in infil-
trative gliomas. This implies that one behavior will have a
direct influence on the other because cells cannot migrate
and proliferate simultaneously. FAK has been previously
demonstrated to stimulate cell cycle progression in vitro
[20,21,39] and specifically in malignant astrocytoma cell
proliferation in vivo [22]. In the current study, dose-response
experiments demonstrated that FAK inhibited glioma cell
migration, which may be correlated to some degree by its ef-
fects on proliferation. Thus, the FAK expression–stimulated
cell cycle progression in both SF767 and G112 glioma cell
lines was associated with decreased cell migration. Con-
versely, expression of Pyk2 stimulated the migration of both
cell types and either inhibited or did not alter cell cycle
progression, consistent with previous results indicating that
Pyk2 and FAK differentially regulate cell cycle progression
[39]. The observed differential effect of Pyk2 on cell cycle
progression in the G112 cells versus the SF767 cells may
potentially be linked to the relative balance between Pyk2
and FAK activity in these cell lines. Indeed, it has been
previously proposed that Pyk2 and FAK may function in an
antagonistic manner [39,52]. Therefore, the addition of ex-
ogenous Pyk2 to SF767 cells, which possess significant
amounts of endogenous active Pyk2 [24], has relatively little
further effect on cell cycle progression. Conversely, the high
endogenous level of Pyk2 may antagonize the capacity of
added exogenous FAK to increase cell cycle progression.
In contrast, the addition of exogenous FAK to G112 cells,
which possess low levels of endogenous active Pyk2, stimu-
lates cell cycle progression to a greater extent than in the
SF767 cells. Similarly, the addition of Pyk2 to G112 cells
effectively antagonizes endogenous FAK and inhibits cell
cycle progression. These results suggest that the balance of
activity between Pyk2 and FAK in glioblastomas may be
particularly relevant to the temporal regulation of tumor cell
growth or migration.
Several Pyk2 mutants were constructed to character-
ize the important functional domains contributing to the
pro-migratory effect of Pyk2 on in vitro migration. Pyk2-
stimulated cell migration required catalytic activity, and an
intact autophosphorylation site as expression of the kinase
dead mutant K457A or the Y402F autophosphorylation
mutant inhibited cell migration. However, an intact auto-
phosphorylation site was not sufficient alone to stimulate
migration. Expression of Pyk2D376, which lacks the NH2-
terminal 376 amino acids and is constitutively phosphory-
lated on Y402, did not stimulate migration relative to
expression of wild-type Pyk2. Notably, cells expressing this
variant migrated at the same rate as cells expressing the
control protein b-galactosidase, suggesting that residues in
the Pyk2 NH2-terminal domain, in addition to the autophos-
phorylation site at Y402, are required for the stimulation of
migration. The importance for Pyk2 N-terminal domain was
further demonstrated through the use of chimeric proteins.
The Pyk/FAK chimera, containing the Pyk2 N-terminal and
kinase domains fused to the C-terminal domain of FAK,
stimulated glioma cell migration to the same extent as wild-
type Pyk2, indicating that the Pyk2 C-terminal domain was
not required for this effect. Interestingly, expression of the
reciprocal FAK/Pyk chimera inhibited glioma cell migration
as effectively as expression wild-type FAK. This suggests
that the FAK kinase domain is required for its inhibitory ef-
fect on migration and that the FAK N-terminal domain can-
not effectively substitute for the Pyk2 N-terminal domain. The
critical role of the Pyk2 N-terminus in the stimulation of gli-
oma cell migration is supported by the observation that ex-
pression of an autonomous Pyk2 amino-terminal 367 amino
acid fragment inhibited glioma cell migration. The amino-
terminal domain of Pyk2 contains a divergent FERM-like
domain [41], and expression of an autonomous Pyk2 FERM
domain significantly inhibits cell migration. Although the
mechanism for this inhibition remains to be determined,
FERM domains have been shown to mediate protein–
protein interactions, as well as to link cytoplasmic proteins
to the plasma membrane [53]. Therefore, the Pyk2 amino-
terminal domain, along with its divergent FERMmotif, could
serve an important functional role by directing Pyk2 mem-
brane localization and by providing a scaffold for the inter-
action with important binding partners and signaling
effectors. Alternatively, the N-terminal domain may function
by regulating Pyk2 activity through intramolecular binding.
An autoinhibitory function for the related N-terminal domain
of FAK has been described [54]. However, we have not
been able to observe an interaction of the Pyk2 N-terminal
domain with endogenous Pyk2 in vitro, consistent with the
results of a recent study [55] suggesting that it is unlikely
that the Pyk2 N-terminal domain has a similar autoregula-
tory function as the FAK N-terminal domain. The mecha-
nism for the effects of these chimeric proteins may be
related to their subcellular localization and is an area of
current investigation.
Proliferation and invasion are integral to the pathogenesis
of glioblastoma, and both phenotypes ultimately need to be
addressed for effective tumor management. Although ac-
tively proliferating cells may be targeted by surgery, localized
radiation, and chemotherapeutic agents directed at DNA
replication, initiation of the migratory phenotype substantially
reduces the effectiveness of these approaches [1,2]. Indeed,
coordinate modulation of apoptosis and migration is demon-
strated by the observation that overexpression of bcl-2
promotes migration and invasion of glioma cells [56]. Con-
versely, inhibition of Rac activity inhibited glioma cell migra-
tion and induced apoptosis [57]. The present study provides
further evidence that the related focal adhesion kinases,
Pyk2 and FAK, function as important regulators of glioblas-
toma cell proliferation and migration. We conclude that Pyk2
plays a central role in glioma cell migration, whereas FAK
activity plays an important role in glioma cell proliferation.
Ongoing studies seek to determine if the roles for Pyk2 and
FAK in determining the invasive or proliferative phenotypes
in vitro are corroborated by studies with glioma cells within
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the context of the brain microenvironment. Understanding
the intracellular signaling networks that trigger glioma cell
migration and invasion could potentially lead to the develop-
ment of novel anti-invasive therapies or approaches that
effectively target migrating cells to increase their suscepti-
bility to current treatment modalities.
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